Howell A, et al. - Authors planned this study to assess uptake and compliance with ovarian suppression using the LHRH analogue, goserelin, with add-back raloxifene, as a potential regimen for breast cancer prevention. In this study, relative to comparable studies, somewhat lower uptake was observed with tamoxifen for prevention with higher drop-out rates. Bone density could be preserved with raloxifene but a reversal of reduction in mammographic density was observed after treatment was completed. Thereby suggesting the possibility of breast cancer risk reduction using LHRH agonists, however reducing toxicity and preventing bone changes would make this a more attractive option.